Oppenheimer Initiates Coverage On Passage Bio with Outperform Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Positive 59.9%

Neg 0% Neu 0% Pos 59.9%

Oppenheimer analyst Jay Olson initiates coverage on Passage Bio (NASDAQ:PASG) with a Outperform rating and announces Price Target of $30.